Get started

Pharmaceuticals

Portfolio Position: Teva Pharmaceuticals $TEVATeva Pharmaceuticals $TEVA has shed over 50% of its value following its $6.1B impairment charge and 75% dividend slash in its latest quarterly report. Pros: - The company continues to expect double digit sales growth from its recent Actavis acquisition from Allergan $AGN. - Teva expects over 1,500 new drugs to launch in 2017, with over 900 drugs still pending approvals. - The company is divesting its non-core organic revenue drivers, expected to bring in over $5B in 2017 and boost margins. - Aggressive cost cutting, saving over $1.6B annually is expected to boost Net Income and Margins. Risks: - Teva's blockbuster drug Copaxone is under competitive pressure, losing market share in 2017 & is expected to continue in 2018. - Sentiment: The company still trades in a highly retail environment being effected by mass hysteria, boding bad for share price. Targets: I initiate TEVA with a $30 PT for the next 12 months, throughout 2018. For the full review: seekingalpha.com
NYSE:TEVALong
by TraderDanER
GILD Long Due to Rebound, Cheap Prince, Indicators in LineI consider GILD to be a great investment because of various factors: Talking fundamentaly, the company has great numbers and a lot of room to expand. It's free cash flow is stunning and the company is way to big to be bought. Technicaly: As you can see, the MACD, RSI and Stochastic are in line, and ready to go up up up. P/E is at a beautiful 6.95. As you can see in the weekly chart, it's just about to go up. I found a good entry point anywhere between 72 and 73 dolars a share due to support levels. GO BIG OR GO HOME.
NASDAQ:GILDLong
by AngelMB95
LLY Eli Lilly: Where can we buy?This stock has been in a correction for about a year now and it looks like it is not done yet. Looking to the price history on the left we can see that we could soon hit strong support starting from $60.00 which is basically the top of a $48-60 price channel. So I would be looking to buy anywhere below $60 if we re-enter that channel (yellow box). I don't expect price to just move through this channel, just like we cannot just break through a herd of cows crossing the street while driving. In addition, if we copy the move from the swing highs to swing lows from 2015-2016 we can see that an equal move would end right around $60 as well, providing a further reason for entry.
NYSE:LLYLong
by PHL
:) PFIZER TOPPED OUT :0GO HSORT GUYS WITH LEAP OPTIONS OF NEEDED. PFIZER TOPPED OUT. buy the rumor sell the news " Pfizer to Buy Medivation for $14 Billion" The bigger the buy the greater the fall. www.wsj.com PFIZER is trying her last bet to survive but eventually will fall. wish Pfizer CEO and all the board directors can see it for them to look for new job or polish up resume or start networking before it gets worse. From 199 high the RED line is touching to new high. As soon as it breaks the light solid (not the dotted one) Green line it will fll pretty hard even though there will be a short term bounce from belwo solid green line but eventually if you hold you short from now on you will be a gainer for coming years. But question is do you have the patience or the risk appetite. Enjoy your lunch guys.
NYSE:PFEShort
by sum1